LataMed AI Corp. (OTC: LMED), a development-stage digital health and artificial intelligence technology company focused on telehealth and healthcare analytics in emerging markets, announced that it has initiated a strategic evaluation to potentially integrate installment-based healthcare payment capabilities through Cashea, a leading buy-now-pay-later platform in Venezuela.
The proposed initiative aims to reduce upfront financial barriers for patients seeking private healthcare services—including consultations, diagnostics, wellness programs, and other eligible offerings—within the LataMed AI ecosystem. Management believes that improving payment accessibility could enhance patient engagement, increase healthcare utilization, and drive broader adoption of the platform. By addressing affordability challenges, the company seeks to strengthen its position as a technology-enabled healthcare marketplace serving patients, providers, and partners throughout Latin America.
Dr. Kevin Rodan Levy, CEO of LataMed AI, stated: “We believe financial accessibility is a critical component of healthcare delivery. Our objective is to evaluate solutions that may help patients obtain timely medical care while simultaneously expanding the reach and utility of our healthcare ecosystem.” He added that such initiatives have the potential to bolster patient acquisition, improve engagement, and support long-term platform growth.
The evaluation process covers operational, technical, and commercial aspects to support a potential integration with Cashea, which is one of Venezuela’s leading buy-now-pay-later financial technology platforms. If successfully completed, the integration could further LataMed AI’s broader strategy of combining artificial intelligence, telehealth infrastructure, care coordination tools, and digital payment accessibility to create a more scalable healthcare marketplace.
As of the date of this release, the company has not entered into a definitive commercial agreement. Completion of any integration remains subject to further commercial discussions, technical implementation requirements, regulatory review, and customary business conditions. LataMed AI intends to provide updates as material developments occur.
For additional information, visit https://latamed.ai or review the company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
